目的 探討前列泰膠囊聯(lián)合左氧氟沙星治療濕熱挾瘀型慢性前列腺炎的臨床療效及其對(duì)前列腺特異性抗原（PSA）、巨噬細(xì)胞炎性蛋白-2（MIP-2）、血管細(xì)胞黏附分子-1（VCAM-1）水平的影響。方法 選取2019年1月—2020年6月于南昌大學(xué)第二附屬醫(yī)院就診的濕熱挾瘀型慢性前列腺炎患者84例作為研究對(duì)象，根據(jù)治療方法將患者分為對(duì)照組（42例）與觀察組（42例）。對(duì)照組患者口服左氧氟沙星片，0.2 g/次，3次/d。觀察組患者在對(duì)照組的基礎(chǔ)上口服前列泰膠囊，5粒/次，3次/d。兩組均持續(xù)治療6周。觀察兩組患者的臨床療效，比較兩組治療前后的美國(guó)國(guó)立衛(wèi)生研究院慢性前列腺炎癥狀指數(shù)（NIH-CPSI）、血清前列腺特異性抗原（PSA）、巨噬細(xì)胞炎性蛋白-2（MIP-2）和血管細(xì)胞黏附分子-1（VCAM-1）水平與尿動(dòng)力學(xué)指標(biāo)。結(jié)果 治療后，觀察組總有效率為95.24%，顯著高于對(duì)照組的78.57%（P<0.05）。治療后，兩組疼痛與不適、排尿癥狀、生活質(zhì)量評(píng)分均低于治療前（P<0.05）；治療后，觀察組疼痛與不適、排尿癥狀、生活質(zhì)量評(píng)分均顯著低于對(duì)照組（P<0.05）。治療后，兩組血清PSA、MIP-2、VCAM-1水平均低于治療前（P<0.05）；治療后，觀察組血清PSA、MIP-2、VCAM-1水平均顯著低于對(duì)照組（P<0.05）。治療后，兩組最大尿流率（MFR）、平均尿流率（AFR）和排尿量均大于治療前（P<0.05）；治療后，觀察組MFR、AFR、排尿量均大于對(duì)照組（P<0.05）。結(jié)論 前列泰膠囊聯(lián)合左氧氟沙星治療濕熱挾瘀型慢性前列腺炎療效肯定，能減輕臨床癥狀，改善尿動(dòng)力學(xué)指標(biāo)，調(diào)節(jié)血清PSA、MIP-2、VCAM-1水平，且未增加不良反應(yīng)發(fā)生。

Objective To investigate the clinical efficacy of Qianlietai Capsules combined with levofloxacin in treatment of chronic prostatitis of damp-heat and blood stasis type and its effects on prostate specific antigen (PSA), macrophage inflammatory protein-2 (MIP-2), vascular cell adhesion molecule-1 (VCAM-1) levels. Methods A total of 84 cases of chronic prostatitis with dampnessheat and stasis in the Second Affiliated Hospital of Nanchang University from January 2019 to June 2020 were selected as the research objects. According to the treatment methods, the patients were divided into control group (42 cases) and observation group (42 cases). Patients in the control group were po administered with Levofloxacin Tablets, 0.2 g/time, three times daily. Patients in the observation group were po administered with Qianlietai Capsules on the basis of control group, 5 capsules/time, 3 times daily. Both groups were treated for 6 weeks. The clinical efficacy of the two groups was observed, and the levels of NIH chronic prostatitis index (NIH-CPSI), serum prostate-specific antigen (PSA), macrophages inflammatory protein-2 (MIP-2), and vascular cell adhesion molecular-1 (VCAM-1) and urodynamic indexes were compared between two groups before and after treatment. Results After treatment, the total effective rate of observation group was 95.24%, which was significantly higher than 78.57% of control group (P < 0.05). After treatment, pain and discomfort, urination symptoms, and quality of life scores in two groups were lower than before treatment (P < 0.05). After treatment, the pain and discomfort, urination symptoms, and quality of life score of observation group were significantly lower than those of control group (P < 0.05). After treatment, the levels of serum PSA, MIP-2, and VCAM-1 in two groups were lower than before treatment (P < 0.05). After treatment, the levels of serum PSA, MIP-2, and VCAM-1 in observation group were significantly lower than those in control group (P < 0.05). After treatment, MFR, AFR and urine volume in two groups were all higher than before treatment (P < 0.05). After treatment, MFR, AFR, and urine volume in the observation group were all higher than those in the control group (P < 0.05). Conclusion Qianlietai Capsules combined with levofloxacin in treatment of chronic prostatitis of damp-heat and blood stasis type is positive. It can reduce clinical symptoms, improve urodynamic indexes, and regulate the levels of serum PSA, MIP-2 and VCAM-1 without increasing the occurrence of adverse reactions.

R983

江西省教育廳科學(xué)技術(shù)研究項(xiàng)目（GJJ161452）；江西省教育廳科學(xué)技術(shù)研究項(xiàng)目（GJJ191408）